Vaccine description | |
---|---|
Target | Smallpox, mpox |
Vaccine type | Attenuated |
Clinical data | |
Trade names | Imvanex, Imvamune, Jynneos |
Other names | MVA |
AHFS/Drugs.com | Professional Drug Facts |
Routes of administration | Subcutaneous, Intradermal[1] |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
ChemSpider |
|
Modified vaccinia Ankara (MVA) is an attenuated (weakened) strain of the vaccinia virus. It is being used as a vaccine (called MVA-BN, brand names: Imvanex in the EU,[3] Imvamune in Canada,[2] and Jynneos in the US[1]) against smallpox and mpox,[4] having fewer side effects than smallpox vaccines derived from other poxviruses.[5]
This third-generation smallpox vaccine has the advantage that it cannot reproduce complete virions in human cells, "the block of the MVA life cycle occurs at the step of virion assembly resulting in assembly of immature virus particles that are not released from the infected cell."[5]
By inserting antigen genes into its genome, modified vaccinia Ankara virus is also used as an experimental viral vector for vaccines against non-poxvirus diseases.[6]
Volz
was invoked but never defined (see the help page).:0
was invoked but never defined (see the help page).